Masimo Corp (MASI) Stock Price & Analysis
Masimo Corp (MASI) rose 0.01% to USD 179.95 as of June 10, 2026 at 00:37 UTC, according to Nexqual real-time market data.
MASI last closed at USD 179.94; the session ranged USD 179.95–179.99 on volume of 3,089,485 shares. Market capitalization is $9.42B, with a 52-week range of USD 125.94–179.99 (NMS). Source: Nexqual, June 10, 2026 at 00:37 UTC.
Key Statistics (as of June 10, 2026 at 00:37 UTC)
| Price | USD 179.95 |
|---|---|
| Change | ▲ 0.01% (up) |
| Previous Close | USD 179.94 |
| Open | USD 179.95 |
| Day Range | USD 179.95 – 179.99 |
| 52-Week Range | USD 125.94 – 179.99 |
| Volume | 3,089,485 shares |
| Market Cap | $9.42B |
| Exchange | NMS |
Technical Analysis (MASI)
Nexqual's technical model rates MASI "BUY" based on 5 bullish and 3 bearish signals across 124 daily candles, as of June 10, 2026 at 00:37 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 74.19 (overbought) |
| vs SMA50 | Above (USD 178.55) |
| MACD | 0.37 (positive) |
Analyst Ratings (MASI)
Wall Street analysts rate MASI "None" based on 4 analysts, with a mean price target of USD 180 (range USD 180–180), per Nexqual as of June 10, 2026 at 00:37 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 180 |
| High Target | USD 180 |
| Low Target | USD 180 |
| Buy / Hold / Sell | 0 / 8 / 0 |
Earnings (MASI)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD 1.41 |
| Revenue Estimate | $398.40M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-09-30 | USD 1.32 vs est 1.2 ▲ beat |
| 2025-06-30 | USD 1.33 vs est 1.22 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:37 UTC.
Financials & Fundamentals (MASI)
| Total Revenue | $1.56B |
|---|---|
| Revenue Growth (YoY) | +8.50% |
| Gross Margin | +61.63% |
| Operating Margin | +23.61% |
| Profit Margin | +4.90% |
| ROE | +24.99% |
| Debt / Equity | 61.59 |
| Current Ratio | 2.68 |
| Total Cash | $124.60M |
| Total Debt | $485.90M |
| Free Cash Flow | $327.92M |
Source: Nexqual, June 10, 2026 at 00:37 UTC.
Financial Health Score (MASI)
Nexqual rates Masimo Corp's overall financial health "Solid" across five dimensions, as of June 10, 2026 at 00:37 UTC.
| Growth | Critical — Revenue -27% YoY (annual), sharp decline |
|---|---|
| Profitability | Strong — Gross margin 62%, operating 24% |
| Balance Sheet | Strong — $125M cash vs $486M debt |
| Cash Flow | Strong — FCF $328M, 21% margin |
| Efficiency | Strong — ROE 25%, ROA 10.2% |
Ownership (MASI)
| Insider Ownership | +6.21% |
|---|---|
| Institutional Ownership | +104.78% |
| Shares Outstanding | 52.37M |
| Float | 44.31M |
| Short % of Float | +7.82% |
Source: Nexqual, June 10, 2026 at 00:37 UTC.
Leadership (MASI)
Masimo Corp is led by Catherine M. Szyman (age 58), CEO & Director, per Nexqual as of June 10, 2026 at 00:37 UTC.
| CEO & Director | Catherine M. Szyman (age 58) |
|---|---|
| Executive VP & CFO | Micah Young (age 46) |
| Executive Vice President of Operations | Anand Sampath (age 59) |
| Chairman of Scientific Advisory Board & Chief Science Officer | Steven J. Barker (age 80) |
| Senior Vice President of FP & A and Investor Relations | Matthew Brinckman |
Major Backers & Investors (MASI)
Notable institutional backers of Masimo Corp include Politan Capital Management LP, Pentwater Capital Management Lp, Barclays Plc, according to Nexqual as of June 10, 2026 at 00:37 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Politan Capital Management LP | 8.76% |
| Pentwater Capital Management Lp | 6.07% |
| Barclays Plc | 5.24% |
| HBK Investments L P | 4.92% |
| Massachusetts Financial Services Co. | 4.47% |
| MFS Series Trust IV-MFS Mid Cap Growth Fund | 3.14% |
| FMR, LLC | 2.77% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 14.62% |
| BlackRock | 11.81% |
| State Street | 3.41% |
Source: Nexqual, June 10, 2026 at 00:37 UTC.
From Masimo Corp's Latest SEC 10-K Filing (filed 2026-02-27)
Key Strengths & Strategy (as disclosed to the SEC)
- Masimo Corporation engages in the development, manufacture, and marketing of various patient monitoring technologies, and automation and connectivity solutions worldwide.
- It offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo Rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of oxygen, carboxyhemoglobin, and methemoglobin.
- It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Iris, iSirona, Replica, and UniView; and brain function monitoring, hemodynamic monitoring, regional oximetry, acoustic respiration rate monitoring, capnography and gas monitoring, and telehealth solutions.
- In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IDXX | IDEXX Laboratories, Inc. | USD 578.89 | ▲ 2.98% |
| GMED | Globus Medical, Inc. | USD 82.52 | ▲ 3.15% |
| PODD | Insulet Corporation | USD 159.61 | ▲ 4.17% |
| DXCM | DexCom, Inc. | USD 78.19 | ▲ 7.32% |
| RMD | ResMed Inc. | USD 196.94 | ▲ 0.46% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:37 UTC. This page is informational and not investment advice.